News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Requests Extension to Review Salix Pharmaceuticals, Ltd. (SLXP) Drug



5/1/2012 7:59:14 AM

Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer

Raleigh-based Salix Pharmaceuticals said Monday that the FDA has extended its review period for a drug that Salix wants to market as a diarrhea relief medication for HIV and AIDS patients.

The new deadline for reviewing the new drug application for Crofelemer is Sept. 5, 2012, a three-month extension. The FDA did not request additional studies on the drug.

The news comes a week after the FDA requested an extension on another Salix (Nasdaq: SLXP) drug – Relistor, to treat constipation in patients on pain medication.




comments powered by Disqus
   
Diarrhea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES